Ultragenyx reports positive long-term data from Phase 1/2 gene therapy studies in GSDIa and OTC deficiency
May 14 2021 - 9:03AM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024